Why did Definium Therapeutics move?
Written after the close on
Definium Therapeutics edged lower as insider selling weighed. Over the last five trading days Definium Therapeutics rose slightly, bucking both a softer market and a clearly weaker healthcare sector, with the gain coming earlier in the stretch before a small pullback in the latest session. The most likely driver is a cluster of insider sales: the chief executive, chief medical officer, chief financial officer and chief commercial officer all sold shares, and several other officers filed notices of intent to sell — insider selling means company executives cashing in part of their own holdings, which can weigh on sentiment. A positive read on the company's depression and anxiety programs likely lent some support earlier, partly offsetting that pressure. Watch the early-November earnings report for the next real test of the story.
Next report: · Add to calendar · Google Calendar
Open Definium Therapeutics's chart